Who Optimizes SG&A Costs Better? Pharming Group N.V. or Xencor, Inc.

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Pharming Group N.V. and Xencor, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Pharming Group's SG&A expenses surged by over 2,000%, peaking in 2022. In contrast, Xencor's expenses grew more steadily, increasing by approximately 615% over the same period.

Pharming Group's expenses saw a dramatic rise, particularly between 2017 and 2022, reflecting strategic investments or perhaps inefficiencies. Meanwhile, Xencor maintained a more consistent growth trajectory, suggesting a balanced approach to cost management. As the biotech industry evolves, these companies' strategies in managing SG&A costs will be pivotal in determining their competitive edge and financial sustainability.